Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener

Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P22+3+6+21+0
S67-1-2+8+0

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

M
2017-03-27
ATRAAtara Biotherapeutics, Inc.Ciechanover Isaac E.CEOS - Sale$20.06-16,0001,208,129-1%-$320,944
D
2017-03-27
KITEKite Pharma, Inc.Butitta Cynthia MCOOS - Sale+OE$77.67-10,000117,795-8%-$776,7460
2017-03-27
ADAPAdaptimmune Therapeutics PlcThompson Peter A.DirP - Purchase$4.20+1,190,4766,149,377+24%+$4,999,999
2017-03-27
ADAPAdaptimmune Therapeutics PlcOrbimed Advisors LLCDirP - Purchase$4.20+1,190,4766,149,377+24%+$4,999,999
2017-03-27
VICLVical IncRamos Anthony AlanVP, Chief Accounting OfficerS - Sale$2.17-4,2509,674-31%-$9,240+5
2017-03-27
ADAPAdaptimmune Therapeutics PlcViswanathan Ravi10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcSonsini Peter W.10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcSandell Scott D10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcMott David MDir, 10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcKerins Patrick J10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcFlorence Anthony A. Jr.10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000+7
2017-03-27
ADAPAdaptimmune Therapeutics PlcBaskett Forest10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000+7
2017-03-27
ADAPAdaptimmune Therapeutics PlcBarris Peter J10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-27
ADAPAdaptimmune Therapeutics PlcBarrett M James10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000+7
DM
2017-03-24
BLUEBluebird Bio, Inc.Lynch DanielDirS - Sale+OE$88.12-3,0001,400-68%-$264,357
2017-03-27
ADAPAdaptimmune Therapeutics PlcNew Enterprise Associates 14, L.P.10%P - Purchase$0.70+12,870,00072,139,000+22%+$9,009,000
2017-03-24
PDLIPdl Biopharma, Inc.Garcia Peter SVP, CFOP - Purchase$1.98+25,000472,842+6%+$49,401+2
2017-03-23
LJPCLa Jolla Pharmaceutical CoTang Kevin CDir, 10%P - Purchase$33.50+149,2543,440,419+5%+$5,000,009-2
2017-03-24
CURNeuralstem, Inc.Lloyd Jones Jonathan BrianCFOP - Purchase$5.50+5,4557,859+227%+$30,003-3
M
2017-03-22
GNMXAevi Genomic Medicine, Inc.Harper Philip R10%P - Purchase$1.78+1,058,5315,065,213+26%+$1,883,650+16
M
2017-03-22
ATRAAtara Biotherapeutics, Inc.McGrath JohnEVP, CFOS - Sale$20.65-14,000112,827-11%-$289,045-1
D
2017-03-21
RGENRepligen CorpDawes Karen ADirS - Sale+OE$34.12-2,52193,243-3%-$86,017+2+2
D
2017-03-20
RGENRepligen CorpBenjamin HowardVP Business DevelopmentS - Sale+OE$34.62-12,21633,908-26%-$422,954+2+2
D
2017-03-20
RGENRepligen CorpRyan Thomas F JrDirS - Sale+OE$34.83-4,0008,594-32%-$139,321+2+2
D
2017-03-20
BCRXBiocryst Pharmaceuticals IncStaab Thomas R IISVP, CFOS - Sale+OE$9.20-3,250141,460-2%-$29,900+3+4
D
2017-03-17
RGENRepligen CorpSnodgres JonCFOS - Sale+OE$34.91-1,90927,789-6%-$66,646+1+2
M
2017-03-16
ATRAAtara Biotherapeutics, Inc.Ciechanover Isaac E.CEOS - Sale$19.38-30,8001,224,129-2%-$596,808-5-3
D
2017-03-16
BLUEBluebird Bio, Inc.Walsh Jeffrey T.Chief FinancialS - Sale+OE$100.07-3,54327,305-11%-$354,563-8-4
2017-03-16
BLUEBluebird Bio, Inc.Sullivan EricPrincipal Accounting OfficerS - Sale$99.00-4116,466-6%-$40,689-8-4
D
2017-03-16
BLUEBluebird Bio, Inc.Lynch DanielDirS - Sale+OE$100.07-2371,400-14%-$23,718-8-4
D
2017-03-16
BLUEBluebird Bio, Inc.Cole JasonGCS - Sale+OE$100.07-4,93012,051-29%-$493,366-8-4
2017-03-15
ATRAAtara Biotherapeutics, Inc.Haqq ChristopherEVP, R, D, Chief Scientific OfS - Sale$19.60-6,000406,855-1%-$117,600+6+5
2017-03-15
VICLVical IncSmith Lawrence RussellVP, Vaccine ResearchS - Sale$2.31-87517,696-5%-$2,0210-3
D
2017-03-15
EDITEditas Medicine, Inc.Glucksmann AlexandraCOOS - Sale+OE$26.41-1,000117,788-1%-$26,410-11-23
2017-03-14
NVAXNovavax IncYoung James FDirS - Sale$1.39-100,000175,000-36%-$138,980-3-10
2017-03-13
BIIBBiogen Inc.Clancy Paul JEVP, CFOS - Sale$291.55-9,89120,705-32%-$2,883,7210-6
D
2017-03-10
TECHBio-Techne CorpLucas Roger CDirS - Sale+OE$107.77-1003,629-3%-$10,777+1-3
D
2017-03-10
BCRXBiocryst Pharmaceuticals IncStaab Thomas R IISVP, CFOS - Sale+OE$9.06-3,250117,313-3%-$29,445-3+7
2017-03-10
JUNOJuno Therapeutics, Inc.Evnin Anthony BDirP - Purchase$22.11+8,00056,990+16%+$176,885+2-1
2017-03-10
ATRAAtara Biotherapeutics, Inc.Soffer GadEVP, Chief Strategy OfficerS - Sale$20.00-2,500266,527-1%-$50,000-11-13
2017-03-10
ATRAAtara Biotherapeutics, Inc.McGrath JohnEVP, CFOS - Sale$20.00-24,000126,827-16%-$480,000+8-12
D
2017-03-09
KITEKite Pharma, Inc.Butitta Cynthia MCOOS - Sale+OE$80.78-21,118117,795-15%-$1,705,929+20
D
2017-03-08
BCRXBiocryst Pharmaceuticals IncStaab Thomas R IISVP, CFOS - Sale+OE$8.43-6,500117,313-5%-$54,763-3-1
2017-03-09
HSKAHeska CorpWisnewski NancyEVP, Diag. Ops, Prod. Dev.S - Sale$96.64-50039,151-1%-$48,321-2-4
D
2017-03-09
HSKAHeska CorpMcMahon JohnVP, CFOS - Sale+OE$97.42-70875-90%-$68,973+30
D
2017-03-09
HSKAHeska CorpLippincott RodEVP, Comp. Animal Health SalesS - Sale+OE$97.87-5,1579,814-34%-$504,721+30
AD
2016-12-06
VBIVVbi Vaccines Inc.Perceptive Advisors LLC10%P - Purchase$3.05+3,383,9556,245,725+118%+$10,321,063+2+6
D
2017-03-06
SGENSeattle Genetics Inc /waSiegall Clay BPres, CEOS - Sale+OE$68.04-14,465636,435-2%-$984,25900
D
2017-03-06
BCRXBiocryst Pharmaceuticals IncStaab Thomas R IISVP, CFOS - Sale+OE$7.90-3,250117,313-3%-$25,675+8+8
2017-03-02
ONCESpark Therapeutics, Inc.Mehra AnandDirS - Sale$65.01-15,275699,430-2%-$993,028-7-5
D
2017-03-03
BLUEBluebird Bio, Inc.Maraganore JohnDirS - Sale+OE$85.02-13,8394,843-74%-$1,176,646-1+6
2017-03-06
HSKAHeska CorpWilson Kevin S.CEO, PresS - Sale$90.00-8,000418,662-2%-$720,000+2+8
D
2017-03-02
HSKAHeska CorpEyl Steven M.EVP, Global Sales, MarketingS - Sale+OE$89.26-10,00011,271-47%-$892,554+2+8
M
2017-03-02
LJPCLa Jolla Pharmaceutical CoTidmarsh George FPres, CEO, SecretaryP - Purchase$34.17+3,0001,354,0860%+$102,505-2+9
2017-03-02
LJPCLa Jolla Pharmaceutical CoCarver JenniferCOOP - Purchase$34.46+1,0003,500+40%+$34,460-2+9
M
2017-03-02
LJPCLa Jolla Pharmaceutical CoChawla Lakhmir SChief Medical OfficerP - Purchase$34.80+1,6002,085+330%+$55,678-2+9
2017-03-03
LJPCLa Jolla Pharmaceutical CoMulroy DennisCFOP - Purchase$33.95+500500New+$16,975-2+9
2017-03-02
LJPCLa Jolla Pharmaceutical CoTang Kevin CDir, 10%P - Purchase$34.64+100,0003,291,165+3%+$3,463,840-2+9
D
2017-03-01
GILDGilead Sciences IncMartin John CExec COBS - Sale+OE$70.38-73,3333,126,636-2%-$5,161,206-1-3
2017-03-01
BIIBBiogen Inc.Sandrock AlfredEVP CMO Neuro, NeurodegeneratS - Sale$290.07-9739,041-10%-$282,238-1-2
M
2017-03-01
CBPOChina Biologic Products, Inc.Shao SeanDirS - Sale$100.78-20,00020,000-50%-$2,015,600-1-2
D
2017-03-01
BLUEBluebird Bio, Inc.Cole JasonGCS - Sale+OE$90.32-5,22512,051-30%-$471,911-2+2
D
2017-03-01
BLUEBluebird Bio, Inc.Schenkein David PDirS - Sale+OE$89.53-5,0002,176-70%-$447,633-2+2
D
2017-03-01
BLUEBluebird Bio, Inc.Lynch DanielDirS - Sale+OE$90.32-2,0001,400-59%-$180,636-2+2
D
2017-03-01
BLUEBluebird Bio, Inc.Davidson DavidChief Medical OfficerS - Sale+OE$89.93-5,00017,177-23%-$449,644-2+2
2017-03-01
CHRSCoherus Biosciences, Inc.Herman Alan C.Chief Scientific OfficerS - Sale$24.19-11,333401,949-3%-$274,171-3-8
M
2017-02-28
CBPOChina Biologic Products, Inc.Gao DavidCEOS - Sale$100.63-116,653395,347-23%-$11,739,3050-1
2017-02-28
BLUEBluebird Bio, Inc.Sullivan EricPrincipal Accounting OfficerS - Sale$89.00-2856,877-4%-$25,365-2-3
D
2017-03-01
ONCESpark Therapeutics, Inc.La Barge JosephGCS - Sale+OE$64.41-5,0005,525-48%-$322,051+2-7
D
2017-03-01
KITEKite Pharma, Inc.Wiezorek JeffreySVP Clinical DevelopmentS - Sale+OE$75.01-18,00021,071-46%-$1,350,144-6-5
D
2017-03-01
KITEKite Pharma, Inc.Chang David DEVP, R, D, Chief Medical OfficS - Sale+OE$79.16-60,00050,165-54%-$4,749,441-6-5
D
2017-03-01
KITEKite Pharma, Inc.Doumani RoyDirS - Sale+OE$74.46-18,800100,130-16%-$1,399,815-6-5
DM
2017-02-28
KITEKite Pharma, Inc.Kim Helen SusanEVP, Business DevelopmentS - Sale+OE$67.78-50,30018,664-73%-$3,409,411-6-5
DM
2017-02-27
KITEKite Pharma, Inc.Butitta Cynthia MCOOS - Sale+OE$73.46-38,882117,795-25%-$2,856,182-6-7
M
2017-02-27
ONCESpark Therapeutics, Inc.Mehra AnandDirS - Sale$65.02-84,654714,705-11%-$5,504,028-4-12-17
2017-02-27
BIIBBiogen Inc.Vounatsos MichelCEOP - Purchase$285.39+1,3331,434>999%+$380,4250-1
D
2017-02-23
GILDGilead Sciences IncWilson Gayle EDirS - Sale+OE$69.30-20,365120,471-14%-$1,411,37400-4
2017-02-24
CURNeuralstem, Inc.Daly Richard JCEOP - Purchase$3.86+2,59115,812+20%+$10,001+8-1+31
2016-11-25
HSKAHeska CorpLarson Sharon J.DirP - Purchase$66.87+1,7501,750New+$117,020+1+9+21
2017-02-22
MNTAMomenta Pharmaceuticals IncWheeler Craig APresS - Sale$15.51-5,626563,306-1%-$87,259+3-4-12
2017-02-22
MNTAMomenta Pharmaceuticals IncKaundinya Ganesh VenkataramanSenior VP, ResearchS - Sale$15.60-1,069490,8370%-$16,676+3-4-12
2017-02-22
MNTAMomenta Pharmaceuticals IncLeicher BruceSVP, GCS - Sale$15.60-1,050175,552-1%-$16,380+3-4-12
2017-02-21
ATRAAtara Biotherapeutics, Inc.McGrath JohnEVP, CFOS - Sale$15.14-9,000150,827-6%-$136,260-1+4+42
2017-02-17
ONCESpark Therapeutics, Inc.Mehra AnandDirS - Sale$65.01-7,535799,359-1%-$489,850-1+4-13
A
2017-02-16
HEBHemispherx Biopharma IncSpringate Wayne S.SVP of OperationsP - Purchase$0.46+8,01416,641+93%+$3,686+7+4+20
2017-02-16
HEBHemispherx Biopharma IncStrayer David RChief Science, Medical OfficerP - Purchase$0.46+9,89233,867+41%+$4,550+7+4+20
2017-02-16
HEBHemispherx Biopharma IncSpringate Wayne S.SVP of OperationsP - Purchase$0.46+8,01431,989+33%+$3,686+7+4+20
2017-02-16
HEBHemispherx Biopharma IncPascale AdamCFOP - Purchase$0.46+6,98111,516+154%+$3,211+7+4+20
2017-02-15
BTXBiotime IncBroadwood Partners, L.P.Dir, 10%P - Purchase$2.70+2,222,22254,301,416+4%+$5,999,999+7+11+16
D
2017-02-15
BLUEBluebird Bio, Inc.Mandell JamesDirS - Sale+OE$80.22-1,0501,000-51%-$84,235+1+7+20
D
2017-02-15
BLUEBluebird Bio, Inc.Lynch DanielDirS - Sale+OE$80.22-1501,400-10%-$12,034+1+7+20
2017-02-15
BLUEBluebird Bio, Inc.Cole JasonGCS - Sale$80.22-66612,051-5%-$53,429+1+7+20
M
2017-02-14
ONCESpark Therapeutics, Inc.Mehra AnandDirS - Sale$65.03-35,347806,894-4%-$2,298,5480-6-10
D
2017-02-16
ATRAAtara Biotherapeutics, Inc.Gallagher Carol GiltnerDirS - Sale+OE$16.10-1,183102,192-1%-$19,0460-5+28
DM
2017-02-14
ATRAAtara Biotherapeutics, Inc.Soffer GadEVP, Chief Strategy OfficerS - Sale+OE$15.42-14,273269,027-5%-$220,1440-5+28
D
2017-02-16
ATRAAtara Biotherapeutics, Inc.Clark Mitchall G.EVP, Chief R, QA OfficerS - Sale+OE$15.96-3,059149,661-2%-$48,8220-5+28
D
2017-02-15
ATRAAtara Biotherapeutics, Inc.Haqq ChristopherEVP, R, D, Chief Scientific OfS - Sale+OE$15.49-7,604412,855-2%-$117,7860-5+28
DM
2017-02-15
ATRAAtara Biotherapeutics, Inc.Ciechanover Isaac E.CEOS - Sale+OE$15.55-4,8001,254,9290%-$74,6640-5+28
D
2017-02-15
EDITEditas Medicine, Inc.Hack Andrew A. F.CFOS - Sale+OE$19.20-3,0000-100%-$57,600+5-5-10
D
2017-02-15
EDITEditas Medicine, Inc.Glucksmann AlexandraCOOS - Sale+OE$20.58-6,000117,788-5%-$123,484+5-5-10

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top